Media Pack
News

Current Edition

JCS Volume 15 Issue 3
 
Regional News

AbbVie, Eli Lilly, Novartis and more cut back in Russia amid corporate exodus over Ukraine war

Since the invasion of Ukraine, hundreds of companies have announced a pause or withdrawal of businesses in Russia. Drugmakers Eli Lilly, Novartis and AbbVie are among...
17 March 2022 Regional News AbbVie | Eli Lilly
Continue Reading →
Regional News

Eyeing its post-Humira future, AbbVie angles for broader Rinvoq use in U.S., Europe

Despite classwide safety worries in the U.S., AbbVie is making strides in its quest to build immunology up-and-comer Rinvoq. AbbVie sent off applications to U.S. and...
11 January 2022 Regional News AbbVie | drug
Continue Reading →
Regional News

As end of New York opioid trial nears, AbbVie’s Allergan ponies up $200M to settle its part of the case

On the day of closing arguments in a high-profile New York opioid trial, AbbVie has inked a $200 million settlement to put the case to bed. AbbVie's Allergan has agr...
13 December 2021 Regional News AbbVie | allergan
Continue Reading →
Regional News

AbbVie’s Rinvoq, Pfizer’s Xeljanz and Lilly’s Olumiant slapped with new FDA warnings amid JAK safety crackdown

The second regulatory shoe has finally dropped for AbbVie, Pfizer and Eli Lilly amid the safety review of JAK inhibitors for inflammatory diseases. But confirmed labe...
8 December 2021 Regional News AbbVie | atopic dermatitis
Continue Reading →
Regional News

AbbVie’s Rinvoq notches Crohn’s disease win amid classwide JAK safety concerns

AbbVie's blockbuster hopeful Rinvoq notched a win in a tricky-to-treat group of Crohn's disease patients, potentially adding another arrow to the company's post-Humir...
8 December 2021 Regional News AbbVie | Crohn's disease
Continue Reading →
Regional News

Alvotech, battling AbbVie over its Humira biosim, raises $450M and tees up Nasdaq debut

Alvotech, the biosim specialist locked in a legal battle over AbbVie's sales Goliath Humira, is revving up for its debut on the Nasdaq. The Icelandic company is join...
8 December 2021 Regional News AbbVie | Alvotech
Continue Reading →
Regional News

AbbVie’s ‘unsupported’ price hikes on Humira drove $1.4B in extra U.S. drug spending, ICER says

Over the years, the Institute for Clinical and Economic Review (ICER) has emerged as a champion in the fight against high U.S. drug costs. In its third report on unsu...
17 November 2021 Regional News AbbVie | drug cost
Continue Reading →
Regional News

Biohaven taps Pfizer for global Nurtec push in deal worth up to $1.24B

Since scoring an FDA approval earlier this year to both treat and prevent migraine, Biohaven’s Nurtec ODT has jumped out ahead of Big Pharma rival AbbVie in garnering...
10 November 2021 Regional News AbbVie | Amgen
Continue Reading →
Regional News

As Revance nears a potential launch for its Botox rival, AbbVie sues for patent infringement

Revance Therapeutics has traveled a long road to a potential FDA approval for its Botox competitor, including COVID delays that pushed back plant inspections. Now, it...
6 October 2021 Regional News AbbVie | Botox
Continue Reading →
Regional News

CEOs of AbbVie, BMS, Lilly, GSK and more raise concerns about Washington’s intensifying drug-pricing push

As officials in Washington weigh contentious drug-pricing measures, there's even more evidence that pharma companies are worried about potential reform. In an open l...
16 September 2021 Regional News AbbVie | Biogen
Continue Reading →
 

jcs-white.png

Journal for Clinical Studies

Journal For Clinical Studies has a distinguished editorial advisory board providing the best guidelines for global clinical trials. Your resource for Multisite Studies and emerging markets.

Facebook Linkedin
Journal For Clinical Studies © 2023, All Rights Reserved – Powered by Teksyte